Project Grant R01AI064576

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a research project to investigate the role of prostaglandin E2 (PGE2) in the immune response to the intracellular pathogen Listeria monocytogenes. The $182,084 award, with a period of performance from November 2024 to October 2026, will fund an unbiased approach to identify bacterial determinants of PGE2 induction,...

Immport Therapeutics, Inc., doing business as Antigen Discovery Inc., received a $642,250 Project Grant award from the United States Department of Agriculture National Institute of Food and Agriculture under the Agriculture and Food Research Initiative competitive grants program. The three-year award will support the development of a state-of-the-art proteomic platform to identify novel diagnostic antigen candidates for the detection of Brucella suis infection in swine. The platform...

The National Institute of Allergy and Infectious Diseases (NIAID), as part of its Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $837,644 Project Grant to Michigan State University (MSU) to develop a comprehensive library of synthetic oligosaccharides targeting the poly-β-(1-6)-N-acetylglucosamine (PNAG) antigen for effective anti-microbial vaccines. The key objectives are to: 1) establish new methodologies to expedite the synthesis of PNAG pentasaccharides with...

This $199,984 Project Grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to increase the fundamental understanding of the immune response to various Lyme disease antigens using bacterial outer membrane vesicles (OMVs) as a novel carrier system. The research objectives are to: 1) explore fusion proteins as a proof of concept to present full Borrelia burgdorferi (BB) antigens on OMVs, 2) determine the potential to express multiple BB antigen epitopes on...

The University of California, Davis received a $225,839 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, titled "Vaccine Induction of Salmonella-Specific Th1 Memory Cells," aims to investigate the role of tissue-resident memory CD4 T cells in providing protection against systemic Salmonella infections, and to evaluate the use of an mRNA nanoparticle vaccine...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $737,502 to The Washington University in St. Louis to investigate the role of the WDFY4 protein in regulating antigen presentation by dendritic cells and the development of regulatory T cells. The research aims to: 1) determine the impact of WDFY4 on the T cell receptor repertoire, particularly in regulatory T cells;...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the molecular regulation and function of lymph node-resident dendritic cells (DC1) in the context of cancer. The $264,750 award aims to investigate how the CD11a integrin regulates DC1 positioning and interactions with migratory dendritic cells to enhance tumor antigen transfer and promote...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) focuses on developing an antibody blockade therapy targeting the novel immune checkpoint LAIR1/CD305. The $398,997 award to Immunogenik, Inc. aims to advance this cancer immunotherapy approach by validating the human anti-LAIR1 antibody (Hu-αLAIR1) in vitro, conducting efficacy studies in tumor-bearing mice, and completing pilot safety/toxicology testing to enable IND-enabling...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $278,390 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to investigate the value of the ESAT-6 antigen for tuberculosis (TB) infection and vaccine development. The project aims to determine whether ESAT-6-specific CD4 T cell responses are beneficial, detrimental, or neutral in M. tuberculosis infection, test if...

This $667,013 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop machine learning models to predict antigen-antibody interactions from high-throughput sequencing data. The key objectives are to: Develop and validate deep learning models to accurately identify antibody-antigen interactions and binding epitopes from massive sequencing data (Aim 1). Integrate B cell...